52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)
Annals of Oncology(2022)
摘要
Topaz-1 was the first phase-III study demonstrating efficacy for the PD-L1 inhibitor durvalumab (D) in combination with gemcitabine (Gem) and cisplatin (Cis), and the combination has the potential to become a new first-line standard of care in biliary tract cancers (BTCs). The aim of this proof-of-concept study was to evaluate the efficacy of tremelimumab (two dosing regimens) in combination with CTx+D.
更多查看译文
关键词
gallbladder carcinoma,cisplatin,gemcitabine,durvalumab
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要